



SDI Review Form 1.6

Journal Name:	International Research Journal of Oncology
Manuscript Number:	Ms_IRJO_49426
Title of the Manuscript:	Benefits of Docetaxel for Metastatic Castration-Resistant Prostate Cancer Sudanese Patients and the Effective Number of Cycle and Dose (2013–2017)
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments		
<u>Minor</u> REVISION comments	is an article that can be called experimental. It is interesting, even if it is a problem restricted to their country. I think it is appropriate to also put the structure of the drug used because we talk about molecules with multiple cycles	This is a retrospective hospital-Based study Data were collected by reviewing medical records using an information sheet.
<u>Optional/General</u> comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	No ethical issues